Novo Nordisk is “no longer the elephant in the room,” analysts led by Kerry Holford said as they upgraded the stock to Buy ...

Eli Lilly (NYSE:LLY) stock has been a huge winner over the past five years, showing gains of more than 400% even when ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Trying to figure out what to do with Eli Lilly stock right now? You are not alone. The last few weeks have been a ...

Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.

In recent years, Lilly's top line has been growing at a much faster pace thanks to its already approved GLP-1 injections, ...

Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth ...

Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem. My general take here is that ...

Now, it’s worth noting Stock Advisor’s total average return is 1,066% — a market-crushing outperformance compared to 186 % ...

Live Updates Live Coverage Updates appear automatically as they are published. Get The Best Vanguard S&P 500 ETF Live ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on Aug. 7. The company beat estimates for both earnings and sales. Sales of ...

The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and ...